Botanix Pharmaceuticals Limited provides an update on its recent quarterly activity, cash flow, and the commercial progress of Sofdra, its treatment for primary axillary hyperhidrosis. Across the company’s materials and accompanying transcript, Botanix discusses operational milestones during the quarter and reviews financial and cash-flow items relevant to its ongoing business. The update focuses specifically on Sofdra’s progress in commercialization, describing factors that influence adoption and sales performance. The company also addresses how it is positioning Sofdra in the market for primary axillary hyperhidrosis, including the status of commercial efforts and any developments that affect revenue timing and growth. In addition, Botanix outlines broader business progress during the period, which includes how resources are being managed and how cash is being used to support operations. Overall, the sources present the update as a routine investor communication covering both financial and business developments tied to Sofdra, without detailing any new regulatory outcomes in the provided excerpts.